Biotech Stocks: Q3 Events to Watch
- The third quarter promises key data releases for several biotech companies.
- MoonLake Immunotherapeutics is expected to release results from its sonelokimab phase 3 VELA studies, which are focused on hidradenitis suppurativa, a chronic inflammatory skin condition.
- Cogent Biosciences is slated to share a readout in July from its bezuclastinib phase 3 SUMMIT study.
Anticipate pivotal Q3 developments shaping the landscape of biotech stocks. MoonLake Immunotherapeutics will unveil Phase 3 VELA study data, poised to influence its market role in dermatology. Cogent Biosciences is set to release SUMMIT study results,possibly expanding its role in treating rare disorders. Investors, already focused on the market role these firms will play, closely watch these catalysts. News Directory 3 provides in-depth analysis of these critical data releases and their impact. Consider the innovative use of biology to solve problems as the future of biotech unfolds. Discover what’s next for these companies and the broader biotech sector.
MoonLake, Cogent Highlight Biotech Stocks Reporting Q3 Results
Updated July 3, 2025
The third quarter promises key data releases for several biotech companies. Investors are keenly focused on the potential market role these results will play. Among the most anticipated are MoonLake Immunotherapeutics and Cogent Biosciences.
MoonLake Immunotherapeutics is expected to release results from its sonelokimab phase 3 VELA studies, which are focused on hidradenitis suppurativa, a chronic inflammatory skin condition. Positive results could substantially boost the company’s stock and its role in the dermatology market.
Cogent Biosciences is slated to share a readout in July from its bezuclastinib phase 3 SUMMIT study. This study addresses indolent systemic mastocytosis, a rare disorder. The market’s role for Cogent could expand significantly wiht favorable outcomes.